Retrovirus

From WikiProjectMed
Jump to navigation Jump to search
"Retrovirology" redirects here. For the journal, see Retrovirology (journal).

Retroviridae
HIV retrovirus schematic of cell infection, virus production and virus structure
Virus classification e
(unranked): Virus
Realm: Riboviria
Kingdom: Pararnavirae
Phylum: Artverviricota
Class: Revtraviricetes
Order: Ortervirales
Family: Retroviridae
Subfamilies and genera[1]

A retrovirus is a type of virus that inserts a DNA copy of its RNA genome into the DNA of a host cell that it invades, thus changing the genome of that cell.[2][3] After invading a host cell's cytoplasm, the virus uses its own reverse transcriptase enzyme to produce DNA from its RNA genome, the reverse of the usual pattern, thus retro (backwards). The new DNA is then incorporated into the host cell genome by an integrase enzyme, at which point the retroviral DNA is referred to as a provirus. The host cell then treats the viral DNA as part of its own genome, transcribing and translating the viral genes along with the cell's own genes, producing the proteins required to assemble new copies of the virus. Many retroviruses cause serious diseases in humans, other mammals, and birds.[4]Retroviruses have many subfamilies in three basic groups:

The specialized DNA-inflitration enzymes in retroviruses make them valuable research tools in molecular biology, and they have been used successfully in gene delivery systems.[8] Evidence from endogenous retroviruses (inherited provirus DNA in animal genomes) suggests that retroviruses have been infecting vertebrates for at least 450 million years.[9]

Classification

Phylogeny of Retroviridae

Exogenous

Exogenous retroviruses are infectious RNA- or DNA-containing viruses that are transmitted from one organism to another. In the Baltimore classification system, which groups viruses together based on their manner of messenger RNA synthesis, they are classified into two groups: Group VI: single-stranded RNA viruses with a DNA intermediate in their life cycle, and Group VII: double-stranded DNA viruses with an RNA intermediate in their life cycle[10].[2]

Group VI viruses

All members of Group VI use virally encoded reverse transcriptase, an RNA-dependent DNA polymerase, to produce DNA from the initial virion RNA genome.[11]

Group VI includes:[12][13]

The family Retroviridae was previously divided into three subfamilies (Oncovirinae, Lentivirinae, and Spumavirinae), but are now divided into two: Orthoretrovirinae and Spumaretrovirinae. The term oncovirus is now commonly used to describe a cancer-causing virus.[14]

Note that according to ICTV 2017, genus Spumavirus has been divided into five genera, and its former type species Simian foamy virus is now upgraded to genus Simiispumavirus with not less than 14 species, including new type species Eastern chimpanzee simian foamy virus.[22]

Group VII viruses

Main article: dsDNA-RT virus

Both families in Group VII have DNA genomes contained within the invading virus particles; the DNA genome is transcribed into both mRNA, for use as a transcript in protein synthesis, and pre-genomic RNA, for use as the template during genome replication.[23]

Group VII includes:[24][25]

The latter family is closely related to the newly proposed:

  • Family Nackednaviridae — e.g. African cichlid nackednavirus (ACNDV), formerly named African cichlid hepatitis B virus (ACHBV).[26]

Whilst families Belpaoviridae, Metaviridae, Pseudoviridae, Retroviridae, and Caulimoviridae constitute the order Ortervirales.[12]

Endogenous

Main article: Endogenous retrovirus

Endogenous retroviruses are not formally included in this classification system, and are broadly classified into three classes, on the basis of relatedness to exogenous genera:[27][28] [29]

  • Class I are most similar to the gammaretroviruses
  • Class II are most similar to the betaretroviruses and alpharetroviruses
  • Class III are most similar to the spumaviruses.

Structure

Characteristics of members of family Retroviridae
Localization of Gag proteins in and near the nucleus[30]

Virions, viruses in the form of independent particles of retroviruses, consist of enveloped particles about 100 nm in diameter. The outer lipid envelope consists of glycoprotein.[31] The virions also contain two identical single-stranded RNA molecules 7–10 kilobases in length. The two molecules are present as a dimer, formed by base pairing between complementary sequences. Interaction sites between the two RNA molecules have been identified as a "kissing stem-loop".[4] Although virions of different retroviruses do not have the same morphology or biology, all the virion components are very similar.[32]

The main virion components are:

  • Envelope: composed of lipids (obtained from the host plasma membrane during the budding process) as well as glycoprotein encoded by the env gene. The retroviral envelope serves three distinct functions: protection from the extracellular environment via the lipid bilayer, enabling the retrovirus to enter/exit host cells through endosomal membrane trafficking, and the ability to directly enter cells by fusing with their membranes.[33][34]
  • RNA: consists of a dimer RNA, it has a cap at the 5' end and a poly(A) tail at the 3' end. Genomic RNA (gRNA) is produced as a result of host RNA polymerase II (Pol II) activity and by adding a 5' methyl cap and a 3' poly-A tail is processed as a host mRNA. The RNA genome also has terminal noncoding regions, which are important in replication, and internal regions that encode virion proteins for gene expression. The 5' end includes four regions, which are R, U5, PBS, and L. The R region is a short repeated sequence at each end of the genome used during the reverse transcription to ensure correct end-to-end transfer in the growing chain. U5, on the other hand, is a short unique sequence between R and PBS. PBS consists of 18 bases complementary to 3' end of tRNA primer. L region is an untranslated leader region that gives the signal for packaging of the genome RNA. The 3' end includes three regions, which are PPT, U3, and R. The PPT is a primer for plus-strand DNA synthesis during reverse transcription. U3 is a sequence between PPT and R, which serves as a signal that the provirus can use in transcription. R is the terminal repeated sequence at 3' end.[35][36][37]
  • Proteins: consisting of gag proteins, protease (PR), pol proteins, and env proteins.
HIV gag protein
    • Group-specific antigen (gag) proteins are major components of the viral capsid, which are about 2000–4000 copies per virion. Gag possesses two nucleic acid binding domains, including matrix (MA) and nucleocapsid (NC). Specifically recognizing, binding, and packaging the retroviral genomic RNA into assembling virions is one of the important functions of Gag protein. Gag interactions with cellular RNAs also regulate aspects of assembly.[38] The expression of gag alone gives rise to assembly of immature virus-like particles that bud from the plasma membrane. In all retroviruses the Gag protein is the precursor to the internal structural protein.[39]
    • Protease (pro) is expressed differently in different viruses. It functions in proteolytic cleavages during virion maturation to make mature gag and pol proteins. Retroviral Gag proteins are responsible for coordinating many aspects of virion assembly.[40][41]
    • Pol proteins are responsible for synthesis of viral DNA and integration into host DNA after infection.[42]
    • Env proteins play a role in association and entry of virions into the host cell. Possessing a functional copy of an env gene is what makes retroviruses distinct from retroelements. The ability of the retrovirus to bind to its target host cell using specific cell-surface receptors is given by the surface component of the Env protein, while the ability of the retrovirus to enter the cell via membrane fusion is imparted by the membrane-anchored trans-membrane component . Thus it is the Env protein that enables the retrovirus to be infectious.[43][44][45][46]
    • Several protein species are associated with the RNA in the retrovirus virion. Nucleocapsid (NC) protein is the most abundant protein, which coats the RNA; while other proteins, present in much smaller amounts and have enzyme activities. Some enzyme activities that are present in the retrovirus virion includes RNA-dependent DNA polymerase (reverse transcriptase; RT), DNA-dependent DNA polymerase, Ribonuclease H (RNase H) Integrase and Protease.[47] The retroviral RNases H encoded by all retroviruses, including HIV have been demonstrated to show three different modes of cleavage: internal, DNA 3′ end-directed, and RNA 5′ end-directed. All three modes of cleavage constitute roles in reverse transcription. Therefore, The RNase H activity is essential in several aspects of reverse transcription. The use of an RNase H activity during retroviral replication displays a unique strategy to copy a single-stranded RNA genome into a double-stranded DNA, since the minus-strand DNA are complementary and make base pairing to retrovirus genome in the first cycle of DNA synthesis.[48] The RNase H ribonuclease activity is also required in the retroviral life cycle, since it generates and removes primers essential by the Reverse Transcriptase (RT) for the initiation of DNA synthesis. Retroviruses that are lacking RNase H activity are noninfectious.[49]

Genomic structure

The genomic and subgenomic organization of a prototypical retrovirus. Abbreviations are explained in the file description.[50]

The retroviral genome is packaged as viral particles. These viral particles are dimers of single-stranded, positive-sense, linear RNA molecules.[37]

Retroviruses (and orterviruses in general) follow a layout of 5'–gag–pro–pol–env–3' in the RNA genome. gag and pol encode polyproteins, each managing the capsid and replication. The pol region encodes enzymes necessary for viral replication, such as reverse transcriptase, protease and integrase.[51] Depending on the virus, the genes may overlap or fuse into larger polyprotein chains. Some viruses contain additional genes. The lentivirus genus, the spumavirus genus, the HTLV / bovine leukemia virus (BLV) genus, and a newly introduced fish virus genus are retroviruses classified as complex. These viruses have genes called accessory genes, in addition to gag, pro, pol and env genes. Accessory genes are located between pol and env, downstream from the env, including the U3 region of LTR, or in the env and overlapping portions. While accessory genes have auxiliary roles, they also coordinate and regulate viral gene expression. In addition, some retroviruses may carry genes called oncogenes or onc genes from another class. Retroviruses with these genes (also called transforming viruses) are known for their ability to quickly cause tumors in animals and transform cells in culture into an oncogenic state.[52]

The polyproteins are cleaved into smaller proteins each with their own function. The nucleotides encoding them are known as subgenes.[50]

Mechanism

A retrovirus has a membrane containing glycoproteins, which are able to bind to a receptor protein on a host cell. There are two strands of RNA within the cell that have three enzymes: protease, reverse transcriptase, and integrase (1). The first step of replication is the binding of the glycoprotein to the receptor protein (2). Once these have been bound, the cell membrane degrades, becoming part of the host cell, and the RNA strands and enzymes enter the cell (3). Within the cell, reverse transcriptase creates a complementary strand of DNA from the retrovirus RNA and the RNA is degraded; this strand of DNA is known as cDNA (4). The cDNA is then replicated, and the two strands form a weak bond and enter the nucleus (5). Once in the nucleus, the DNA is integrated into the host cell's DNA with the help of integrase (6). This cell can either stay dormant, or RNA may be synthesized from the DNA and used to create the proteins for a new retrovirus (7). Ribosome units are used to translate the mRNA of the virus into the amino acid sequences which can be made into proteins in the rough endoplasmic reticulum. This step will also make viral enzymes and capsid proteins (8). Viral RNA will be made in the nucleus. These pieces are then gathered together and are pinched off of the cell membrane as a new retrovirus (9).

When retroviruses have integrated their own genome into the germ line, their genome is passed on to a following generation. These endogenous retroviruses (ERVs), contrasted with exogenous ones, now make up 5–8% of the human genome.[28] Most insertions have no known function and are often referred to as "junk DNA". However, many endogenous retroviruses play important roles in host biology, such as control of gene transcription, cell fusion during placental development in the course of the germination of an embryo, and resistance to exogenous retroviral infection. Endogenous retroviruses have also received special attention in the research of immunology-related pathologies, such as autoimmune diseases like multiple sclerosis, although endogenous retroviruses have not yet been proven to play any causal role in this class of disease.[53]

While transcription was classically thought to occur only from DNA to RNA, reverse transcriptase transcribes RNA into DNA. The term "retro" in retrovirus refers to this reversal (making DNA from RNA) of the usual direction of transcription. It still obeys the central dogma of molecular biology, which states that information can be transferred from nucleic acid to nucleic acid but cannot be transferred back from protein to either protein or nucleic acid. Reverse transcriptase activity outside of retroviruses has been found in almost all eukaryotes, enabling the generation and insertion of new copies of retrotransposons into the host genome. These inserts are transcribed by enzymes of the host into new RNA molecules that enter the cytosol. Next, some of these RNA molecules are translated into viral proteins. The proteins encoded by the gag and pol genes are translated from genome-length mRNAs into Gag and Gag–Pol polyproteins. In example, for the gag gene; it is translated into molecules of the capsid protein, and for the pol gene; it is translated into molecules of reverse transcriptase. Retroviruses need a lot more of the Gag proteins than the Pol proteins and have developed advanced systems to synthesize the required amount of each. As an example, after Gag synthesis nearly 95 percent of the ribosomes terminate translation, while other ribosomes continue translation to synthesize Gag–Pol. In the rough endoplasmic reticulum glycosylation begins and the env gene is translated from spliced mRNAs in the rough endoplasmic reticulum, into molecules of the envelope protein. When the envelope protein molecules are carried to the Golgi complex, they are divided into surface glycoprotein and transmembrane glycoprotein by a host protease. These two glycoprotein products stay in close affiliation, and they are transported to the plasma membrane after further glycosylation.[4]

It is important to note that a retrovirus must bring its own reverse transcriptase in its capsid, otherwise it is unable to utilize the enzymes of the infected cell to carry out the task, due to the unusual nature of producing DNA from RNA.[54]Industrial drugs that are designed as protease and reverse-transcriptase inhibitors are made such that they target specific sites and sequences within their respective enzymes. However these drugs can quickly become ineffective due to the fact that the gene sequences that code for the protease and the reverse transcriptase quickly mutate.[55] [56][57]

Because reverse transcription lacks the usual proofreading of DNA replication, a retrovirus mutates very often. This enables the virus to grow resistant to antiviral pharmaceuticals quickly, and impedes the development of effective vaccines and inhibitors for the retrovirus.[58]

One difficulty faced with some retroviruses, such as the Moloney retrovirus, involves the requirement for cells to be actively dividing for transduction. As a result, cells such as neurons are very resistant to infection and transduction by retroviruses.[59]

Recombination

Two RNA genomes are packaged into each retrovirus particle, but, after an infection, each virus generates only one provirus.[60] After infection, reverse transcription occurs and this process is accompanied by recombination. Recombination involves template strand switching between the two genome copies (copy choice recombination) during reverse transcription. From 5 to 14 recombination events per genome occur at each replication cycle.[61] Genetic recombination appears to be necessary for maintaining genome integrity and as a repair mechanism for salvaging damaged genomes.[60]

Transmission

In terms of transmission of retroviruses we find that they can are spread via unprotected sexual contact, as well as, exposure of infected blood, exposure of infected tissue, and during pregnancy from parent to child[62][63] Hence transmission is done via:

Provirus

The DNA formed after reverse transcription (the provirus) is longer than the RNA genome because each of the terminals have the U3 - R - U5 sequences called long terminal repeat (LTR). Thus, 5' terminal has the extra U3 sequence, while the other terminal has the U5 sequence.[47] LTRs are able to send signals for vital tasks to be carried out such as initiation of RNA production or management of the rate of transcription. This way, LTRs can control replication, hence, the entire progress of the viral cycle.[67] Although located in the nucleus, the non-integrated retroviral cDNA is a very weak substrate for transcription. For this reason, an integrated provirus is a necessary for permanent and an effective expression of retroviral genes.[37]

This DNA can be incorporated into host genome as a provirus that can be passed on to progeny cells; the retrovirus DNA is inserted at random into the host genome. Because of this, it can be inserted into oncogenes. In this way some retroviruses can convert normal cells into cancer cells. Some provirus remains latent in the cell for a long period of time before it is activated by the change in cell environment.[68][69][1][70]

Gene therapy

Typical lentiviral vector backbone plasmid

Gammaretroviral and lentiviral vectors for gene therapy have been developed that mediate stable genetic modification of treated cells by chromosomal integration of the transferred vector genomes. This technology is of use, not only for research purposes, but also for clinical gene therapy aiming at the long-term correction of genetic defects, e.g., in stem and progenitor cells. Retroviral vector particles with tropism for various target cells have been designed. Gammaretroviral and lentiviral vectors have so far been used in more than 300 clinical trials, addressing treatment options for various diseases.[8][71]

Retroviral mutations can be developed to make transgenic mouse models to study various cancers .[72]

Oncogenicity

Retroviruses that cause tumor growth include Rous sarcoma virus and mouse mammary tumor virus. Cancer can be triggered by proto-oncogenes that were mistakenly incorporated into proviral DNA or by the disruption of cellular proto-oncogenes. Rous sarcoma virus contains the src gene that triggers tumor formation. Later it was found that a similar gene in cells is involved in cell signaling, which was most likely excised with the proviral DNA. Nontransforming viruses can randomly insert their DNA into proto-oncogenes, disrupting the expression of proteins that regulate the cell cycle. The promoter of the provirus DNA can also cause over expression of regulatory genes. Retroviruses can cause diseases such as cancer and immunodeficiency. If viral DNA is integrated into host chromosomes, it can lead to permanent infections. It is therefore important to discover the body's response to retroviruses. Exogenous retroviruses are especially associated with pathogenic diseases. For example, mice have mouse mammary tumor virus (MMTV), which is a retrovirus. This virus passes to newborn mice through mammary milk. When they are 6 months old, the mice carrying the virus get mammary cancer because of the retrovirus. In addition, leukemia virus I (HTLV-1), found in human T cell, has been found in humans for many years. It is estimated that this retrovirus causes leukemia in the ages of 40 and 50.[73] It has a replicable structure that can induce cancer. In addition to the usual gene sequence of retroviruses, HTLV-1 contains a fourth region, PX. This region encodes Tax, Rex, p12, p13 and p30 regulatory proteins. The Tax protein initiates the leukemic process and organizes the transcription of all viral genes in the integrated HTLV proviral DNA. [74]

Treatment

Antiretroviral drugs are medications for the treatment of infection by retroviruses, primarily HIV. Different classes of antiretroviral drugs act on different stages of the HIV life cycle. Combination of several (typically three or four) antiretroviral drugs is known as highly active antiretroviral therapy (HAART).[75]

Treatment of veterinary retroviruses

Feline leukemia virus and Feline immunodeficiency virus infections are treated with biologics, including the only immunomodulator currently licensed for sale in the United States, Lymphocyte T-Cell Immune Modulator (LTCI).[76]

Early evolution

Studies of retroviruses led to the first demonstrated synthesis of DNA from RNA templates, a fundamental mode for transferring genetic material that occurs in both eukaryotes and prokaryotes. It has been speculated that the RNA to DNA transcription processes used by retroviruses may have first caused DNA to be used as genetic material; in this model, the RNA world hypothesis, cellular organisms adopted the more chemically stable DNA when retroviruses evolved to create DNA from the RNA templates.[77][78][79]

An estimate of the date of evolution of the foamy-like endogenous retroviruses placed the time of the most recent common ancestor at > 450 million years ago.[80][81]

Notes

1.^ Not a journal reference, however important to the understanding of provirus as a source

References

  1. ↑ "Virus Taxonomy: 2018b Release". International Committee on Taxonomy of Viruses (ICTV). March 2019. Archived from the original on 20 March 2020. Retrieved 16 March 2019.
  2. ↑ 2.0 2.1 Cloyd, Miles W. (1996). "Human Retroviruses". Medical Microbiology (4th ed.). University of Texas Medical Branch at Galveston. ISBN 978-0-9631172-1-2. Archived from the original on 1 May 2023. Retrieved 9 December 2023.
  3. ↑ "retrovirus". Oxford English Dictionary. Archived from the original on 26 September 2018. Retrieved 25 September 2018.
  4. ↑ 4.0 4.1 4.2 Carter JB, Saunders VA (2007). Virology: principles and applications (1st ed.). Chichester, England: John Wiley & Sons. p. 191. ISBN 978-0-470-02386-0. OCLC 124160564.
  5. ↑ Coffin JM, Hughes SH, Varmus HE, eds. (1997). Retroviruses. Cold Spring Harbor Laboratory. ISBN 978-0-87969-571-2.
  6. ↑ Narayan, Opendra; Clements, Janice E. (1989). "Biology and Pathogenesis of Lentiviruses". Journal of General Virology. 70 (7): 1617–1639. doi:10.1099/0022-1317-70-7-1617. ISSN 1465-2099. Archived from the original on 13 July 2023. Retrieved 15 December 2023.
  7. ↑ {Miller, A. D. (2006). Retroviral Vectors in Gene Therapy. Encyclopedia of Life Sciences. doi:10.1038/npg.els.0005741}
  8. ↑ 8.0 8.1 Kurth R, Bannert N, eds. (2010). Retroviruses: Molecular Biology, Genomics and Pathogenesis. Horizon Scientific. ISBN 978-1-904455-55-4. Archived from the original on 29 August 2023. Retrieved 14 August 2023.
  9. ↑ Zheng, Jialu; Wei, Yutong; Han, Guan-Zhu (1 February 2022). "The diversity and evolution of retroviruses: Perspectives from viral "fossils"". Virologica Sinica. 37 (1): 11–18. doi:10.1016/j.virs.2022.01.019. ISSN 1995-820X. PMC 8922424. PMID 35234634.
  10. ↑ Kyriakou, Eleni; Magiorkinis, Gkikas (September 2023). "Interplay between endogenous and exogenous human retroviruses". Trends in Microbiology. 31 (9): 933–946. doi:10.1016/j.tim.2023.03.008. ISSN 1878-4380. Archived from the original on 19 May 2023. Retrieved 10 December 2023.
  11. ↑ Berman, Jules J. (2019). "Viruses". Taxonomic Guide to Infectious Diseases: 263–319. doi:10.1016/B978-0-12-817576-7.00007-9. Archived from the original on 23 May 2022. Retrieved 17 December 2023.
  12. ↑ 12.0 12.1 Krupovic, M; Blomberg, J; Coffin, JM; Dasgupta, I; Fan, H; Geering, AD; Gifford, R; Harrach, B; Hull, R; Johnson, W; Kreuze, JF; Lindemann, D; Llorens, C; Lockhart, B; Mayer, J; Muller, E; Olszewski, N; Pappu, HR; Pooggin, M; Richert-Pöggeler, KR; Sabanadzovic, S; Sanfaçon, H; Schoelz, JE; Seal, S; Stavolone, L; Stoye, JP; Teycheney, PY; Tristem, M; Koonin, EV; Kuhn, JH (4 April 2018). "Ortervirales: New virus order unifying five families of reverse-transcribing viruses". Journal of Virology. 92 (12): e00515–18. doi:10.1128/JVI.00515-18. PMC 5974489. PMID 29618642.
  13. ↑ "Taxonomy browser (Ortervirales)". www.ncbi.nlm.nih.gov. Archived from the original on 23 April 2022. Retrieved 21 December 2023.
  14. ↑ Petropoulos, C. (1997). "Retroviral Taxonomy, Protein Structures, Sequences, and Genetic Maps". Retroviruses. Cold Spring Harbor Laboratory Press. Archived from the original on 29 June 2023. Retrieved 17 December 2023.
  15. ↑ Coffin, John; Blomberg, Jonas; Fan, Hung; Gifford, Robert; Hatziioannou, Theodora; Lindemann, Dirk; Mayer, Jens; Stoye, Jonathan; Tristem, Michael; Johnson, Welkin (2021). "ICTV Virus Taxonomy Profile: Retroviridae 2021". Journal of General Virology. 102 (12): 001712. doi:10.1099/jgv.0.001712. ISSN 1465-2099. Archived from the original on 27 March 2023. Retrieved 14 December 2023.
  16. ↑ "Taxonomy browser (Orthoretrovirinae)". www.ncbi.nlm.nih.gov. Archived from the original on 22 December 2023. Retrieved 21 December 2023.
  17. ↑ "Genus: Alpharetrovirus | ICTV". ictv.global. Archived from the original on 22 December 2023. Retrieved 21 December 2023.
  18. ↑ "Genus: Betaretrovirus | ICTV". ictv.global. Archived from the original on 22 December 2023. Retrieved 21 December 2023.
  19. ↑ "Genus: Gammaretrovirus | ICTV". ictv.global. Archived from the original on 22 December 2023. Retrieved 21 December 2023.
  20. ↑ "Genus: Deltaretrovirus | ICTV". ictv.global. Archived from the original on 16 March 2023. Retrieved 21 December 2023.
  21. ↑ Khan, Arifa S.; Bodem, Jochen; Buseyne, Florence; Gessain, Antoine; Johnson, Welkin; Kuhn, Jens H.; Kuzmak, Jacek; Lindemann, Dirk; Linial, Maxine L.; Löchelt, Martin; Materniak-Kornas, Magdalena; Soares, Marcelo A.; Switzer, William M. (1 March 2018). "Spumaretroviruses: Updated taxonomy and nomenclature". Virology. 516: 158–164. doi:10.1016/j.virol.2017.12.035. ISSN 0042-6822.
  22. ↑ ICTV Taxonomy Archived 20 March 2020 at the Wayback Machine Browser
  23. ↑ "dsDNA(RT) replication/transcription". ViralZone. Swiss Institute of Bioinformatics. Archived from the original on 19 September 2020. Retrieved 6 August 2020.
  24. ↑ Magnius, Lars; Mason, William S.; Taylor, John; Kann, Michael; Glebe, Dieter; Dény, Paul; Sureau, Camille; Norder, Heléne (2020). "ICTV Virus Taxonomy Profile: Hepadnaviridae". The Journal of General Virology. 101 (6): 571–572. doi:10.1099/jgv.0.001415. ISSN 0022-1317. Archived from the original on 12 December 2023. Retrieved 10 December 2023.
  25. ↑ Teycheney, PY; Geering, ADW; Dasgupta, I; Hull, R; Kreuze, JF; Lockhart, B; Muller, E; Olszewski, N; Pappu, H; Pooggin, MM; Richert-Pöggeler, KR; Schoelz, JE; Seal, S; Stavolone, L; Umber, M; ICTV Report Consortium (October 2020). "ICTV Virus Taxonomy Profile: Caulimoviridae". The Journal of General Virology. 101 (10): 1025–1026. doi:10.1099/jgv.0.001497. PMC 7660458. PMID 32940596.
  26. ↑ Lauber C, Seitz S, Mattei S, Suh A, Beck J, Herstein J, et al. (September 2017). "Deciphering the Origin and Evolution of Hepatitis B Viruses by Means of a Family of Non-enveloped Fish Viruses". Cell Host & Microbe. 22 (3): 387–399.e6. doi:10.1016/j.chom.2017.07.019. PMC 5604429. PMID 28867387. and PDF
  27. ↑ Nelson PN, Hooley P, Roden D, Davari Ejtehadi H, Rylance P, Warren P, et al. (October 2004). "Human endogenous retroviruses: transposable elements with potential?". Clinical and Experimental Immunology. 138 (1): 1–9. doi:10.1111/j.1365-2249.2004.02592.x. PMC 1809191. PMID 15373898.
  28. ↑ 28.0 28.1 Belshaw R, Pereira V, Katzourakis A, Talbot G, Paces J, Burt A, Tristem M (April 2004). "Long-term reinfection of the human genome by endogenous retroviruses". Proceedings of the National Academy of Sciences of the United States of America. 101 (14): 4894–4899. Bibcode:2004PNAS..101.4894B. doi:10.1073/pnas.0307800101. PMC 387345. PMID 15044706.
  29. ↑ Bustamante Rivera, Yomara Y.; Brütting, Christine; Schmidt, Caroline; Volkmer, Ines; Staege, Martin S. (2018). "Endogenous Retrovirus 3 – History, Physiology, and Pathology". Frontiers in Microbiology. 8. doi:10.3389/fmicb.2017.02691. ISSN 1664-302X. Archived from the original on 28 June 2022. Retrieved 22 December 2023.
  30. ↑ Stake, Matthew S.; Bann, Darrin V.; Kaddis, Rebecca J.; Parent, Leslie J. (18 November 2013). "Nuclear trafficking of retroviral RNAs and Gag proteins during late steps of replication". Viruses. 5 (11): 2767–2795. doi:10.3390/v5112767. ISSN 1999-4915. PMC 3856414. PMID 24253283.
  31. ↑ Coffin, John M.; Hughes, Stephen H.; Varmus, Harold E. (1997). The Place of Retroviruses in Biology. Cold Spring Harbor Laboratory Press. Archived from the original on 7 January 2023. Retrieved 14 August 2023.
  32. ↑ Coffin JM (1992). "Structure and Classification of Retroviruses". In Levy JA (ed.). The Retroviridae. Vol. 1 (1st ed.). New York: Plenum. p. 20. ISBN 978-0-306-44074-8.
  33. ↑ Hansen, Dorte Tranberg; Petersen, Thor; Christensen, Tove (15 September 2017). "Retroviral envelope proteins: Involvement in neuropathogenesis". Journal of the Neurological Sciences. 380: 151–163. doi:10.1016/j.jns.2017.07.027. ISSN 0022-510X.
  34. ↑ Harrison, Stephen C. (1 January 2005). "Mechanism of Membrane Fusion by Viral Envelope Proteins". Advances in Virus Research. Academic Press. 64: 231–261. Archived from the original on 19 November 2023. Retrieved 15 December 2023.
  35. ↑ Coffin, John M.; Hughes, Stephen H.; Varmus, Harold E. (1997). "Processing of Retroviral RNA". Retroviruses. Cold Spring Harbor Laboratory Press. Archived from the original on 20 January 2023. Retrieved 13 December 2023.
  36. ↑ Coffin, John M.; Hughes, Stephen H.; Varmus, Harold E. (1997). "Virion RNA". Retroviruses. Cold Spring Harbor Laboratory Press. Archived from the original on 19 December 2023. Retrieved 17 December 2023.
  37. ↑ 37.0 37.1 37.2 Painter, Mark M.; Collins, Kathleen L. (1 January 2019), "HIV and Retroviruses", in Schmidt, Thomas M. (ed.), Encyclopedia of Microbiology (Fourth Edition), Academic Press, pp. 613–628, doi:10.1016/b978-0-12-801238-3.66202-5, ISBN 978-0-12-811737-8, S2CID 188750910, archived from the original on 3 November 2021, retrieved 3 May 2020
  38. ↑ Olson ED, Musier-Forsyth K (February 2019). "Retroviral Gag protein-RNA interactions: Implications for specific genomic RNA packaging and virion assembly". Seminars in Cell & Developmental Biology. SI: Human dendritic cells. 86: 129–139. doi:10.1016/j.semcdb.2018.03.015. PMC 6167211. PMID 29580971.
  39. ↑ Coffin JM, Hughes SH, Varmus HE (1997). Virion Proteins. Cold Spring Harbor Laboratory Press. ISBN 978-0-87969-571-2. Archived from the original on 29 August 2023. Retrieved 14 August 2023.
  40. ↑ "CDD Conserved Protein Domain Family: RVP_2". www.ncbi.nlm.nih.gov. Archived from the original on 2 August 2021. Retrieved 11 December 2023.
  41. ↑ Bond, Judith S. (1 February 2019). "Proteases: History, discovery, and roles in health and disease". The Journal of Biological Chemistry. 294 (5): 1643–1651. doi:10.1074/jbc.TM118.004156. ISSN 0021-9258. Archived from the original on 24 July 2023. Retrieved 11 December 2023.
  42. ↑ Hill, Melissa; Tachedjian, Gilda; Mak, Johnson (January 2005). "The packaging and maturation of the HIV-1 Pol proteins". Current HIV research. 3 (1): 73–85. doi:10.2174/1570162052772942. ISSN 1570-162X. Archived from the original on 23 January 2023. Retrieved 13 December 2023.
  43. ↑ "New Insights of How the HIV-1 Assembles and Incorporates the Env Protein | Advanced Photon Source". www.aps.anl.gov. Archived from the original on 31 March 2023. Retrieved 14 December 2023.
  44. ↑ Kim FJ, Battini JL, Manel N, Sitbon M (January 2004). "Emergence of vertebrate retroviruses and envelope capture". Virology. 318 (1): 183–91. doi:10.1016/j.virol.2003.09.026. PMID 14972546.
  45. ↑ Coffin, John M.; Hughes, Stephen H.; Varmus, Harold E. (1997). "Synthesis and Organization of Env Glycoproteins". Retroviruses. Cold Spring Harbor Laboratory Press. Archived from the original on 22 December 2023. Retrieved 19 December 2023.
  46. ↑ Coffin 1992, pp. 26–34
  47. ↑ 47.0 47.1 Carter JB, Saunders VA (2007). Virology : principles and applications. Chichester, England: John Wiley & Sons. ISBN 978-0-470-02386-0. OCLC 124160564.
  48. ↑ Champoux JJ, Schultz SJ (June 2009). "RNase H Activity: Structure, Specificity, and Function in Reverse Transcription". The FEBS Journal. 134 (1–2): 86–103. doi:10.1016/j.virusres.2007.12.007. PMC 2464458. PMID 18261820.
  49. ↑ Moelling K, Broecker F, Kerrigan JE (2014). "RNase H: specificity, mechanisms of action, and antiviral target". Human Retroviruses. Methods in Molecular Biology. Vol. 1087. pp. 71–84. doi:10.1007/978-1-62703-670-2_7. ISBN 978-1-62703-669-6. PMID 24158815.
  50. ↑ 50.0 50.1 Vargiu L, Rodriguez-Tomé P, Sperber GO, Cadeddu M, Grandi N, Blikstad V, et al. (January 2016). "Classification and characterization of human endogenous retroviruses; mosaic forms are common". Retrovirology. 13: 7. doi:10.1186/s12977-015-0232-y. PMC 4724089. PMID 26800882.
  51. ↑ Peters, P. J., Marston, B. J., Weidle, P. J., & Brooks, J. T. (2013). Human Immunodeficiency Virus Infection. Hunter’s Tropical Medicine and Emerging Infectious Disease, 217–247. doi:10.1016/b978-1-4160-4390-4.00027-8
  52. ↑ Coffin JM, Hughes SH, Varmus HE (1997). "Genetic Organization". Retroviruses. Cold Spring Harbor Laboratory Press. ISBN 978-0-87969-571-2. Archived from the original on 8 March 2021. Retrieved 14 August 2023.
  53. ↑ Medstrand P, van de Lagemaat LN, Dunn CA, Landry JR, Svenback D, Mager DL (2005). "Impact of transposable elements on the evolution of mammalian gene regulation". Cytogenetic and Genome Research. 110 (1–4): 342–52. doi:10.1159/000084966. PMID 16093686. S2CID 25307890.
  54. ↑ HUGHES, STEPHEN H. (2015). "Reverse Transcription of Retroviruses and LTR Retrotransposons". Microbiology spectrum. 3 (2): MDNA3–0027–2014. doi:10.1128/microbiolspec.MDNA3-0027-2014. ISSN 2165-0497. Archived from the original on 16 March 2021. Retrieved 26 December 2023.
  55. ↑ Dunn, Ben M.; Goodenow, Maureen M.; Gustchina, Alla; Wlodawer, Alexander (26 March 2002). "Retroviral proteases". Genome Biology. 3 (4): reviews3006.1. doi:10.1186/gb-2002-3-4-reviews3006. ISSN 1474-760X. Archived from the original on 23 March 2023. Retrieved 26 December 2023.
  56. ↑ Patel, Parth H.; Zulfiqar, Hassam (2023). "Reverse Transcriptase Inhibitors". StatPearls. StatPearls Publishing. Archived from the original on 23 November 2023. Retrieved 26 December 2023.
  57. ↑ "Antiretroviral Treatment of Human Immunodeficiency Virus (HIV) Infection - Infections". MSD Manual Consumer Version. Archived from the original on 16 June 2023. Retrieved 26 December 2023.
  58. ↑ Svarovskaia ES, Cheslock SR, Zhang WH, Hu WS, Pathak VK (January 2003). "Retroviral mutation rates and reverse transcriptase fidelity". Frontiers in Bioscience. 8 (1–3): d117–34. doi:10.2741/957. PMID 12456349.
  59. ↑ Wong, P. K. Y. (1990). Moloney Murine Leukemia Virus Temperature-Sensitive Mutants: A Model for Retrovirus-Induced Neurologic Disorders. Springer. pp. 29–60. ISBN 978-3-642-75267-4. Archived from the original on 10 June 2018. Retrieved 20 December 2023.
  60. ↑ 60.0 60.1 Rawson JM, Nikolaitchik OA, Keele BF, Pathak VK, Hu WS (November 2018). "Recombination is required for efficient HIV-1 replication and the maintenance of viral genome integrity". Nucleic Acids Research. 46 (20): 10535–10545. doi:10.1093/nar/gky910. PMC 6237782. PMID 30307534.
  61. ↑ Cromer D, Grimm AJ, Schlub TE, Mak J, Davenport MP (January 2016). "Estimating the in-vivo HIV template switching and recombination rate". AIDS. 30 (2): 185–92. doi:10.1097/QAD.0000000000000936. PMID 26691546. S2CID 20086739.
  62. ↑ Coffin, John M.; Hughes, Stephen H.; Varmus, Harold E. (1997). "Transmission and Epidemiology". Retroviruses. Cold Spring Harbor Laboratory Press. Archived from the original on 16 September 2021. Retrieved 9 December 2023.
  63. ↑ Greenwood, Alex D.; Ishida, Yasuko; O'Brien, Sean P.; Roca, Alfred L.; Eiden, Maribeth V. (March 2018). "Transmission, Evolution, and Endogenization: Lessons Learned from Recent Retroviral Invasions". Microbiology and Molecular Biology Reviews. 82 (1). doi:10.1128/MMBR.00044-17. ISSN 1092-2172. Archived from the original on 13 December 2023. Retrieved 12 December 2023.
  64. ↑ Jolly C (March 2011). "Cell-to-cell transmission of retroviruses: Innate immunity and interferon-induced restriction factors". Virology. 411 (2): 251–9. doi:10.1016/j.virol.2010.12.031. PMC 3053447. PMID 21247613.
  65. ↑ Bekker, Linda-Gail; Beyrer, Chris; Mgodi, Nyaradzo; Lewin, Sharon R.; Delany-Moretlwe, Sinead; Taiwo, Babafemi; Masters, Mary Clare; Lazarus, Jeffrey V. (17 August 2023). "HIV infection". Nature Reviews Disease Primers. 9 (1): 1–21. doi:10.1038/s41572-023-00452-3. ISSN 2056-676X. Archived from the original on 19 October 2023. Retrieved 24 December 2023.
  66. ↑ Miller, A. Dusty; De las Heras, Marcelo; Yu, Jingyou; Zhang, Fushun; Liu, Shan-Lu; Vaughan, Andrew E.; Vaughan, Thomas L.; Rosadio, Raul; Rocca, Stefano; Palmieri, Giuseppe; Goedert, James J.; Fujimoto, Junya; Wistuba, Ignacio I. (20 January 2017). "Evidence against a role for jaagsiekte sheep retrovirus in human lung cancer". Retrovirology. 14 (1): 3. doi:10.1186/s12977-017-0329-6. ISSN 1742-4690. Archived from the original on 29 November 2022. Retrieved 15 December 2023.
  67. ↑ MacLachlan, N. James; Dubovi, Edward J. (2011). Fenner's Veterinary Virology (Fourth ed.). Academic Press. p. 250. ISBN 978-0-12-375159-1. Retrieved 6 May 2020.
  68. ↑ Rabson, A. B.; Graves, B. J. (1997). "Synthesis and Processing of Viral RNA". Retroviruses. Cold Spring Harbor Laboratory Press. ISBN 978-0-87969-571-2. Archived from the original on 29 August 2023. Retrieved 12 December 2023.
  69. ↑ "Retroviruses and the Genetic Origins of Cancer, 1970-1993". Harold Varmus - Profiles in Science. 12 March 2019. Archived from the original on 10 November 2023. Retrieved 24 December 2023.
  70. ↑ Gallo, Robert C.; Marvin S. Reitz, Jr (2003). "Mechanisms of Oncogenesis". Holland-Frei Cancer Medicine. 6th edition. BC Decker. Archived from the original on 25 December 2023. Retrieved 24 December 2023.
  71. ↑ Desport M, ed. (2010). Lentiviruses and Macrophages: Molecular and Cellular Interactions. Caister Academic. ISBN 978-1-904455-60-8.
  72. ↑ Kumar, T. Rajendra; Larson, Melissa; Wang, Huizhen; McDermott, Jeff; Bronshteyn, Illya (2009). "Transgenic Mouse Technology: Principles and Methods". Methods in molecular biology (Clifton, N.J.). 590: 335–362. doi:10.1007/978-1-60327-378-7_22. ISSN 1064-3745. Archived from the original on 25 May 2022. Retrieved 12 December 2023.
  73. ↑ Ross, S. R. (2018). Cellular Immune Responses to Retroviruses. In Retrovirus-Cell Interactions (pp. 401–420). Elsevier. https://doi.org/10.1016/B978-0-12-811185-7.00011-X Archived 29 August 2023 at the Wayback Machine
  74. ↑ Burrell, C. J., Howard, C. R., & Murphy, F. A. (2017). Retroviruses. In Fenner and White’s Medical Virology (pp. 317–344). Elsevier. https://doi.org/10.1016/b978-0-12-375156-0.00023-0 Archived 29 August 2023 at the Wayback Machine
  75. ↑ Rutherford GW, Sangani PR, Kennedy GE (2003). "Three- or four- versus two-drug antiretroviral maintenance regimens for HIV infection". The Cochrane Database of Systematic Reviews (4): CD002037. doi:10.1002/14651858.CD002037. PMID 14583945.
  76. ↑ Gingerich DA (2008). "Lymphocyte T-cell immunomodulator (LTCI): Review of the immunopharmacology of a new biologic" (PDF). International Journal of Applied Research in Veterinary Medicine. 6 (2): 61–68. ISSN 1559-470X. Archived (PDF) from the original on 13 July 2011. Retrieved 14 August 2023.
  77. ↑ Hayward, Alexander (2017). "Origin of the retroviruses: when, where, and how?". Current Opinion in Virology. 25: 23–27. doi:10.1016/j.coviro.2017.06.006. ISSN 1879-6257. Archived from the original on 8 August 2023. Retrieved 11 December 2023.
  78. ↑ Neveu, Marc; Kim, Hyo-Joong; Benner, Steven A. (April 2013). "The "Strong" RNA World Hypothesis: Fifty Years Old". Astrobiology. 13 (4): 391–403. doi:10.1089/ast.2012.0868. ISSN 1531-1074. Archived from the original on 28 August 2021. Retrieved 12 December 2023.
  79. ↑ Alberts, Bruce; Johnson, Alexander; Lewis, Julian; Raff, Martin; Roberts, Keith; Walter, Peter (2002). "The RNA World and the Origins of Life". Molecular Biology of the Cell. 4th edition. Garland Science. Archived from the original on 10 June 2023. Retrieved 20 December 2023.
  80. ↑ Aiewsakun P, Katzourakis A (January 2017). "Marine origin of retroviruses in the early Palaeozoic Era". Nature Communications. 8: 13954. Bibcode:2017NatCo...813954A. doi:10.1038/ncomms13954. PMC 5512871. PMID 28071651.
  81. ↑ Johnson, Welkin E. (June 2019). "Origins and evolutionary consequences of ancient endogenous retroviruses". Nature Reviews Microbiology. 17 (6): 355–370. doi:10.1038/s41579-019-0189-2. ISSN 1740-1534. Archived from the original on 27 January 2023. Retrieved 18 December 2023.

Further reading

External links

Retrieved from "https://mdwiki.org/w/index.php?title=Retrovirus&oldid=1392262"